Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: February 1, 2023

Details for Patent: 8,778,997

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,778,997 protect, and when does it expire?

Patent 8,778,997 protects RAPIVAB and is included in one NDA.

This patent has forty patent family members in fourteen countries.

Summary for Patent: 8,778,997

Title:	Antiviral treatments
Abstract:	The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
Inventor(s):	Babu; Yarlagadda Sudhakara (Birmingham, AL), Chand; Pooran (Birmingham, AL), Bantia; Shanta (Birmingham, AL), Arnold; Shane (Hoover, AL), Kilpatrick; John Michael (Helena, AL)
Assignee:	BioCryst Pharmaceuticals, Inc. (Birmingham, AL)
Application Number:	13/103,562
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,778,997

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biocryst	RAPIVAB	peramivir	SOLUTION;INTRAVENOUS	206426-001	Dec 19, 2014		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER	See Plans and Pricing
Biocryst	RAPIVAB	peramivir	SOLUTION;INTRAVENOUS	206426-001	Dec 19, 2014		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS	See Plans and Pricing
Biocryst	RAPIVAB	peramivir	SOLUTION;INTRAVENOUS	206426-001	Dec 19, 2014		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,778,997

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006341592	See Plans and Pricing
Australia	2007215156	See Plans and Pricing
Australia	2013216632	See Plans and Pricing
Australia	2016262644	See Plans and Pricing
Brazil	PI0621552	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic

Boehringer Ingelheim

Merck

Dow

McKesson

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.